Aisha S. Sie

Nijmegen, GE, Netherlands

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 14 publications

Universal Tumor DNA BRCA1/2 Testing of Ovarian Cancer: Prescreening PARPi Treatment and Genetic Predisposition.

Universal Tumor DNA BRCA1/2 Testing of Ovarian Cancer: Prescreening PARPi Treatment and Genetic Predisposition.

Journal: Journal of the National Cancer Institute

Published: January 23, 2019

An online self-test added to colorectal cancer screening can increase the effectiveness of familial cancer risk assessment without increasing distress.

An online self-test added to colorectal cancer screening can increase the effectiveness of familial cancer risk assessment without increasing distress.

Journal: Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland

Published: February 06, 2018

Online self-test identifies women at high familial breast cancer risk in population-based breast cancer screening without inducing anxiety or distress.

Online self-test identifies women at high familial breast cancer risk in population-based breast cancer screening without inducing anxiety or distress.

Journal: European journal of cancer (Oxford, England : 1990)

Published: January 22, 2017

Novel BRCA1 and BRCA2 Tumor Test as Basis for Treatment Decisions and Referral for Genetic Counselling of Patients with Ovarian Carcinomas.

Novel BRCA1 and BRCA2 Tumor Test as Basis for Treatment Decisions and Referral for Genetic Counselling of Patients with Ovarian Carcinomas.

Journal: Human mutation

Published: June 08, 2016

Lifestyle Risk Factors for Breast Cancer in BRCA1/2-Mutation Carriers Around Childbearing Age.

Lifestyle Risk Factors for Breast Cancer in BRCA1/2-Mutation Carriers Around Childbearing Age.

Journal: Journal of genetic counseling

Published: March 17, 2016

Stopping ovarian cancer screening in BRCA1/2 mutation carriers: effects on risk management decisions & outcome of risk-reducing salpingo-oophorectomy specimens.

Stopping ovarian cancer screening in BRCA1/2 mutation carriers: effects on risk management decisions & outcome of risk-reducing salpingo-oophorectomy specimens.

Journal: Maturitas

Published: December 17, 2014

High Satisfaction and Low Distress in Breast Cancer Patients One Year after BRCA-Mutation Testing without Prior Face-to-Face Genetic Counseling.

High Satisfaction and Low Distress in Breast Cancer Patients One Year after BRCA-Mutation Testing without Prior Face-to-Face Genetic Counseling.

Journal: Journal of genetic counseling

Published: September 17, 2014

Easy-to-use decision aids for improved cancer family history collection and use among oncology practices.

Easy-to-use decision aids for improved cancer family history collection and use among oncology practices.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: September 04, 2014

Fourfold increased detection of Lynch syndrome by raising age limit for tumour genetic testing from 50 to 70 years is cost-effective.

Fourfold increased detection of Lynch syndrome by raising age limit for tumour genetic testing from 50 to 70 years is cost-effective.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: August 02, 2014

Patient experiences with gene panels based on exome sequencing in clinical diagnostics: high acceptance and low distress.

Patient experiences with gene panels based on exome sequencing in clinical diagnostics: high acceptance and low distress.

Journal: Clinical genetics

Published: February 13, 2014

More breast cancer patients prefer BRCA-mutation testing without prior face-to-face genetic counseling.

More breast cancer patients prefer BRCA-mutation testing without prior face-to-face genetic counseling.

Journal: Familial cancer

Published: September 27, 2013

Can we test for hereditary cancer at 18 years when we start surveillance at 25? Patient reported outcomes.

Can we test for hereditary cancer at 18 years when we start surveillance at 25? Patient reported outcomes.

Journal: Familial cancer

Published: April 23, 2013

Showing 1-12 of 14

Last Updated: 09/26/2026